Intravenously Transplanted Human Multilineage-Differentiating Stress-Enduring Cells Afford Brain Repair in a Mouse Lacunar Stroke Model
Authors:
- 1 February 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (2) , 601-611
Abstract
Background and Purpose—: Multilineage-differentiating stress-enduring cells are endogenous nontumorigenic reparative pluripotent-like stem cells found in bone marrow, peripheral blood, and connective tissues. Topically administered human multilineage-differentiating stress-enduring cells into rat/mouse stroke models differentiated into neural cells and promoted clinically relevant functional recovery. However, critical questions on the appropriate timing and dose, and safety of the less invasive intravenous administration of clinical-grade multilineage-differentiating stress-enduring cell–based product CL2020 remain unanswered. Methods—: Using an immunodeficient mouse lacunar model, CL2020 was administered via the cervical vein in different doses (high dose=5×10 4 cells/body; medium dose=1×10 4 cells/body; low dose=5×10 3 cells/body) at subacute phase (≈9 days after onset) and chronic phase (≈30 days). Cylinder test, depletion of human cells by diphtheria toxin administration, immunohistochemistry, and human specific-genome detection were performed. Results—: Tumorigenesis and adverse effects were not detected for up to 22 weeks. The high-dose group displayed significant functional recovery compared with the vehicle group in cylinder test in subacute-phase–treated and chronic-phase–treated animals after 6 weeks and 8 weeks post-injection, respectively. In the high-dose group of subacute-phase–treated animals, robust and stable recovery in cylinder test persisted up to 22 weeks compared with the vehicle group. In both groups, intraperitoneal injection of diphtheria toxin abrogated the functional recovery. Anti-human mitochondria revealed CL2020 distributed mainly in the peri-infarct area at 1, 10, and 22 weeks and expressed NeuN (neuronal nuclei)- and MAP-2 (microtubule-associated protein-2)-immunoreactivity. Conclusions—: Intravenously administered CL2020 was safe, migrated to the peri-infarct area, and afforded functional recovery in experimental stroke.Keywords
This publication has 36 references indexed in Scilit:
- Muse Cells Are Endogenous Reparative Stem Cells2018
- S1P–S1PR2 Axis Mediates Homing of Muse Cells Into Damaged Heart for Long-Lasting Tissue Repair and Functional Recovery After Acute Myocardial InfarctionCirculation Research, 2018
- Mobilized Muse Cells After Acute Myocardial Infarction Predict Cardiac Function and Remodeling in the Chronic PhaseCirculation Journal, 2018
- Mobilization of Pluripotent Multilineage-Differentiating Stress-Enduring Cells in Ischemic StrokeJournal of Stroke and Cerebrovascular Diseases, 2016
- A Distinct Subpopulation of Bone Marrow Mesenchymal Stem Cells, Muse Cells, Directly Commit to the Replacement of Liver ComponentsAmerican Journal of Transplantation, 2015
- Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cellsNature Protocols, 2013
- Stem Cell Therapy for Cerebral Ischemia: From Basic Science to Clinical ApplicationsJournal of Cerebral Blood Flow & Metabolism, 2012
- Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblastsProceedings of the National Academy of Sciences, 2011
- Unique multipotent cells in adult human mesenchymal cell populationsProceedings of the National Academy of Sciences, 2010
- Optimizing the success of cell transplantation therapy for strokeNeurobiology of Disease, 2010